Skip to main content
Fig. 4 | BMC Nephrology

Fig. 4

From: Guidelines adherence in the prevention and management of chronic kidney disease in patients with diabetes mellitus on the background of recent European recommendations – a registry-based analysis

Fig. 4

Proportion of patients using SGLT-2 as per guideline recommendation.  Legend: Treatment with an SGLT2 inhibitor (empagliflozin, canagliflozin or dapagliflozin) is associated with a lower risk of renal endpoints and is recommended* if eGFR is 30 to < 90 mL/min/1.73 m2) [3]. Analyses restricted to the last treatment year; values are percent with 95 % CIs; *Although evidence is very limited for patients with T1DM

Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us